바이바이바이오🤡DS 제약/바이오 김민정

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT® this year, with four indications overall

WALTHAM, Mass., September 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition cha

UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.

[더바이오 지용준 기자] GC녹십자의 1차 면역결핍증 치료제인 ‘알리글로(ALYGLO)’가 미국 주요 보험사 3곳의 처방집(formulary)에 등재됐다. 환자 투여도 본격적으로 이뤄지면서 시장에 순조롭게 진입했다.GC녹십자는 시그나헬스케어(Cigna Healthcare), 유나이티드

The BIOSECURE Act would prohibit the U.S. government from contracting with, or providing grants to, U.S. companies doing business with five Chinese companies.

[프라임경제] T 세포 기반 면역치료 글로벌 선도 기업인 네오이뮨텍(950220)은 현지시간으로 오는 13일부터 17일까지 스페인 바르셀로나에서 열리는 유럽종양학회(European Society for Medical Oncology, ESMO)에서 CAR-T 치료제와 자사 면역치료제 NT-I7(물질명 efineptakin alfa)을 병용한 1b 임상시험(NIT-112)의 중간 결과를 발표한다고 9일 밝혔다.